Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019067087) GEMELLA SANGUINIS AS A BIOTHERAPEUTICS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/067087 International Application No.: PCT/US2018/045329
Publication Date: 04.04.2019 International Filing Date: 06.08.2018
IPC:
C12R 1/01 (2006.01) ,A23K 10/18 (2016.01) ,A23L 33/135 (2016.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
R
INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C-C12Q75
1
Micro-organisms
01
Bacteria or actinomycetales
[IPC code unknown for A23K 10/18][IPC code unknown for A23L 33/135]
Applicants:
SECOND GENOME, INC. [US/US]; 341 Allerton Avenue South San Francisco, California 94080, US
Inventors:
HAN, Andrew Wonhee; US
RAJA, Bernat Baeza; US
KAWANA, Shoko; US
YAMAMOTO, Mitsuko Lynn; US
DABBAGH, Karim; US
DESANTIS, Todd Zachary; US
Agent:
HOLLY, David Christopher; US
HAN, Jong-Jin; US
TUSCAN, Michael S.; US
VEITENHEIMER, Erich E.; US
Priority Data:
62/563,12426.09.2017US
Title (EN) GEMELLA SANGUINIS AS A BIOTHERAPEUTICS
(FR) GEMELLA SANGUINIS EN TANT QU'AGENTS BIOTHÉRAPEUTIQUES
Abstract:
(EN) The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat various human diseases. In some aspects, the disclosure provides such compositions comprising strains of the bacterium Gemella sanguinis and their uses in treating metabolic-related diseases or disorder.
(FR) L'invention concerne des produits biothérapeutiques vivants, des probiotiques, des compositions pharmaceutiques comportant lesdits probiotiques, et leurs procédés d'utilisation pour traiter diverses maladies humaines. Selon certains modes de réalisation, l'invention concerne de telles compositions comportant des souches de la bactérie Gemella sanguinis et leurs utilisations dans le traitement de maladies ou de troubles liés au métabolisme.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)